Kadans Science Partner has acquired 75,000 sq ft Windrush Court in Oxford in a sale and lease back deal.
The whole building will be leased back to vendor and occupier Oxford Biomedica in the deal which expands Kadans’ pan-European portfolio. EG has reported the purchase price as £60 million.
James Sheppard, managing director (UK & Ireland) for Kadans, said: “We are delighted to secure this tremendously important asset in the Oxford ecosystem. Oxford Biomedica is one of the world’s leading companies in cell and gene therapy, an area of deep specialism for Kadans and we look forward to building a relationship with the team.”
Stuart Paynter, chief financial officer of Oxford Biomedica, said: “We are pleased to have exchanged contracts for the sale and leaseback of our state-of-the-art Windrush Court facility and look forward to building a relationship with Kadans, the European leader in the development and management of life sciences buildings and ecosystems.
“The proceeds of the transaction will enhance our net cash position, providing us with additional financial flexibility as we build our leadership as an innovation-led CDMO (contract development and manufacturing organisation) across all viral vectors for cell and gene therapy.”
Knight Frank acted for Kadans, with Mills & Reeve as legal advisor. CBRE advised the Oxford Biomedica with Plainlaw as legal advisor.
© Thames Tap (powered by ukpropertyforums.com).
Sign up to receive your free weekly Thames Tap journal here.